Abstracts tagged "rheumatoid arthritis (RA) and viruses"

Abstract Number: 2876 • 2018 ACR/ARHP Annual Meeting
Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
Paul Studenic¹, Gregor Bond², Andreas Kerschbaumer³, Manuel Bécède³, Karel Pavelka⁴, Dmitry Karateev⁵, Jutta Stieger⁶, Rudolf Puchner⁷, Ruediger Mueller⁸, Elisabeth Puchhammer-Stöckl⁹, Martina Durechova¹⁰, Michaela Loiskandl¹⁰, Thomas Perkmann¹¹, Marta Olejarova⁴, Elena Luchikhina¹², Carl-Walter Steiner¹³, Michael Bonelli¹⁰, Josef S. Smolen¹⁴ and Daniel Aletaha¹⁰, ¹Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Internal Medicine 3, Division of Nephrology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Experimental Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University in Prague, Prague, Czech Republic, ⁵Department of Rheumatology, Department of Rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, ⁶2nd Deparment of Medicine, 2nd Deparment of Medicine, Hitzing Hospital, Vienna, Austria, ⁷Private Office, Wels, Austria, ⁸Division of Rheumatology, Immunology and Rehabilitation, Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Institute for Virology, Institute for Virology, Medical University of Vienna, Vienna, Austria, ¹⁰Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹¹Department of Laboratory Medicine, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ¹²Department of rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, ¹³Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients who fail to respond to methotrexate (MTX) can be subjected to an addition of biologic disease-modifying antirheumatic drug (bDMARD). Currently…
Abstract Number: 2428 • 2017 ACR/ARHP Annual Meeting
Epstein-Barr Virus Infection and Epstein-Barr Virus　Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis
Shotaro Masuoka¹, Natsuko Kusunoki¹, Shinichi Kawai² and Toshihiro Nanki¹, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Department of Inflammation and Pain Control Research, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Epstein-Barr virus (EBV) infection causes various malignant tumors such as B cell lymphoma and epithelial cell cancer. Previous reports showed several variants in carboxyl-terminal…
Abstract Number: 2032 • 2015 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis
Olga S. Zhukov¹, Rania W. Abolhosn¹, Jonnielyn G. Rivera¹, Mary Lape Nixon², Robert J. Lagier³, Harry E. Prince⁴, Hollis J. Batterman⁴ and Stanley J. Naides¹, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Lab Sciences, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Lab Services, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA
Background/Purpose: Chikungunya fever virus (CHIK) is emerging in the western hemisphere as a mosquito-borne, acute onset arthritis. The majority of cases progress to persistent moderate…
Abstract Number: 3193 • 2015 ACR/ARHP Annual Meeting
Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis
Jonathan Miner¹, Lindsey Cook¹, Raeann Shimak², Julie Fox¹, Alissa Young¹, Kristen Monte², Subhajit Poddar², Michael Diamond¹ and Deborah Lenschow¹, ¹Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that has infected more than 1 million individuals in the Western Hemisphere since 2014. …
Abstract Number: 2159 • 2014 ACR/ARHP Annual Meeting
Human T-Lymphotropic Virus Type 1 Biomarkers in Patients with Rheumatoid Arthritis
Akihiko Okayama¹, Masako Iwanaga², Yasuko Sagara³, Toshihiko Hidaka⁴, Kunihiko Umekita⁵, Kazumi Nakano⁶, Toshiki Watanabe⁶, Yoshihisa Yamano⁷, Yoshiro Horai⁸, Hideki Nakamura⁹ and Atsushi Kawakami⁹, ¹Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, ²The Jikei University of School of Medicine, Tokyo, Japan, ³Japanese Red Cross Kyushu Block Blood Center, Fukuoka, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵University of Miyazaki, Miyazaki, Japan, ⁶Laboratory of Tumor Cell Biology, Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan, ⁷Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, ⁸Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL). It has been debated recently whether or not immunosuppressive…
Abstract Number: L12 • 2014 ACR/ARHP Annual Meeting
Immunological Phenotyping of a Cohort of American Travelers with Chikungunya Viral Arthritis
Jonathan Miner¹, Han Xian Aw yeang¹, Julie Fox¹, Samantha Taffner¹, Alfred Kim², Michael Diamond¹, Deborah Lenschow³ and Wayne Yokoyama^1,4, ¹Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ³Washington University in Saint Louis School of Medicine, Saint Louis, MO, ⁴Howard Hughes Medical Institute, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that spread to the United States in 2014. After an initial period of acute…
Abstract Number: 1390 • 2013 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3n (eta) In Rheumatoid Arthritis and Arthritogenic Viral Infections
Stanley J. Naides, Olga S Zhukov, Rania W Abolhosn and Joanna M Popov, Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
Background/Purpose: The 14-3-3 proteins are ubiquitously-expressed intracellular chaperonins. Expression of the η (eta) isoform is restricted to synovial and CNS tissues. Extracellular 14-3-3η induces proinflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].